Rigel Pharma (RIGL) Misses Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported Q1 EPS of ($0.40), $0.04 worse than the analyst estimate of ($0.36).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel launches breast cancer drug Veppanu at $29,400 per month
- McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
- Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
